Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities

This article was originally published in The Pink Sheet Daily

Executive Summary

For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.

You may also be interested in...

Simeprevir Clears FDA, But Tougher Road Lies Ahead

Unlike HCV competitors Incivek and Victrelis, Janssen’s second-generation protease inhibitor Olysio carries a recommendation for screening to weed out patients with a hepatitis C variant associated with poor response – but the strength of its efficacy and safety should still beat out those drugs. The harder part will be gaining share as patients are opting to wait for even better regimens.

Is It A Rash Or Photosensitivity? FDA May Have To Distinguish Them In Simeprevir Label

Antiviral Drugs Advisory Committee members debated whether both adverse reactions should be included in the simeprevir label’s “Warnings and Precautions” section and whether photosensitivity should automatically lead to stopping treatment.

EASL Spotlight: Liver Docs Gear Up For Wave Of New Hep C Drugs, Expect Change Soon

Publication of four Phase III studies for Gilead’s sofosbuvir in the New England Journal of Medicine reassures analysts on the safety front. But while Gilead is in the lead, its sofosbuvir-centered regimens will also face competition from several other promising new Hep C regimens in development.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts